Loading patent…
AssigneeEpis S.A.
InventorJacob Bar-Tana
Estimating the term…
A novel class of compounds has been found to be effective in blocking cholesterol and neutral lipid synthesis in-vivo without adversely affecting energy metabolism, useful for the treatment of obesity, hyperlipidemia and maturity-onset diabetes. The active compounds have the general formula ##STR1## or in-vivo hydrolyzable functional derivatives of the carboxylic groups thereof, wherein R.sub.1 and R.sub.2 each independently represents an unsubstituted or substituted hydrocarbyl or hetercyclyl radical; X and Y each independently represents hydrogen, optionally substituted lower alkyl, halogen, cyano, carboxy, lower alkoxycarbonyl or carbamoyl; and Q represents a diradical consisting of a linear chain of 8 to 14 carbon atoms, one or more of which may be replaced by heteroatoms, said chain being optionally substituted by inert substituents and one or more of said carbon or heteratom chain members optionally forming part of a ring structure.
A pharmaceutical composition comprising, as active ingredient, at least one pharmaceutically acceptable compound of the general formula ##STR9## or an in-vivo hydrolyzable functional derivative selected from the group consisting of salts with pharmaceutically acceptable inorganic or organic cations;
A pharmaceutical composition comprising, together with a solid or liquid pharmaceutically acceptable carrier, diluent or excipient, at least one pharmaceutically acceptable compound selected from the group consisting of:
Dependencies are inferred from the claim text.